Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yongfeng Yu,Qisen Guo,Yongchang Zhang,Jian Fang,Diansheng Zhong,Baogang Liu,Pinhua Pan,Dongqing Lv,Lin Wu,Yanqiu Zhao,Juan Li,Zhihua Liu,Chunling Liu,Haichuan Su,Yun Fan,Tongmei Zhang,Anwen Liu,Bo Jin,Ye Wang,Jianying Zhou,Zhihong Zhang,Fengming Ran,Xia Song,Michael Shi,Weiguo Su,Shun Lu,Yongfeng Yu,Qisen Guo,Yongchang Zhang,Jian Fang,Diansheng Zhong,Baogang Liu,Pinhua Pan,Dongqing Lv,Lin Wu,Yanqiu Zhao,Juan Li,Zhihua Liu,Chunling Liu,Haichuan Su,Yun Fan,Tongmei Zhang,Anwen Liu,Bo Jin,Ye Wang,Jianying Zhou,Zhihong Zhang,Fengming Ran,Xia Song,Mengzhao Wang,Xiaodong Zhang,Rui Ma,Zizheng Song,Xingya Li,Ying Cheng,Changli Wang,Liang Han,Jianhua Shi,Zhuang Yu,Yuan Chen,Jianan Huang,Xuhong Min,Limin Wang,Kaihua Lu,Minglei Yang,Pingli Wang,Xiaorong Dong,Guohua Yu,Buhai Wang,Jianhua Chang,Jianchun Duan,Shundong Cang,Quanyi Song,Jie Yu,Songhua Fan,Linfang Wang,Yongxin Ren,Xian Luo,Michael Shi,Weiguo Su,Shun Lu
DOI: https://doi.org/10.1016/s2213-2600(24)00211-x
IF: 102.642
2024-09-13
The Lancet Respiratory Medicine
Abstract:Summary Background Savolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 ( MET ex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced or metastatic MET ex14-mutated NSCLC. Methods This single-arm, multicohort, multicentre, open-label, phase 3b study was done at 48 hospitals in China in adult (≥18 years) patients with locally advanced or metastatic MET ex14-mutated NSCLC who had not received previous systemic antitumour therapy. Patients with a bodyweight of 50 kg or more and those with a bodyweight of less than 50 kg received savolitinib once daily at 600 mg or 400 mg, respectively, in 21-day cycles. The primary endpoint was objective response rate assessed by independent review committee (IRC) per Response Evaluation Criteria in Solid Tumours, version 1.1. The full analysis set comprised all patients who received at least one dose of study medication, which was used to assess the efficacy endpoints and baseline and safety data. This study is registered with ClinicalTrials.gov (NCT04923945) and is closed to accrual. Findings Between Aug 31, 2021, and Oct 20, 2023, 125 treatment-naive patients were assessed for eligibility, of whom 87 were enrolled and received savolitinib. The median age of patients was 70·0 years (IQR 65·2–75·8) and 51 (59%) of 87 patients were male and 36 (41%) were female. In the full analysis set, the IRC-assessed objective response rate was 62% (95% CI 51–72) and the investigator-assessed objective response rate was 60% (49–70), showing a high concordance rate (84%). Treatment-related adverse events were reported in 85 (98%) of 87 patients, with peripheral oedema (54 [62%]) being the most common. Two of these treatment-related adverse events led to death (cardiac failure n=1, unknown reasons n=1). Interpretation Savolitinib showed manageable toxicity and promising efficacy in treatment-naive patients with advanced or metastatic MET ex14-mutated NSCLC. Funding HUTCHMED and AstraZeneca.
respiratory system,critical care medicine